Skip to content

Homogenization of the effectiveness of the "in-person remote" diabetes self-management support model for the comprehensive management of patients with type 2 diabetes mellitus: a national multicenter real-world retrospective study

Homogenization of the effectiveness of the "in-person remote" diabetes self-management support model for the comprehensive management of patients with type 2 diabetes mellitus: a national multicenter real-world retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085048
Enrollment
Unknown
Registered
2024-05-30
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patients who have completed initial registration from October 2016 to December 2023 in a national multi-center management cohort that conducts diabetes shared care clinics; 2. patients with type 2 diabetes; 3. aged >18 years.

Exclusion criteria

Exclusion criteria: 1. patients who, as of December 2023, have been withdrawn from follow-up in the diabetes shared care outpatient management cohort for various reasons; 2. patients with non-type 2 diabetes such as pre-diabetes, type 1 diabetes, and specific types of diabetes.

Design outcomes

Primary

MeasureTime frame
Annual changes from baseline HbA1c and its in target rate;Annual changes from baseline BP and its in target rate;Annual changes from baseline LDL-c and its in target rate;

Secondary

MeasureTime frame
Annual changes from baseline BMI and its in target rate;Annual change from the baseline on self-management behavior scale score;Annual change from baseline on self-efficacy scale score;Annual change from baseline on A-DQOL score;Annual changes in Morisky medication compliance score scale compared with the baseline;Annual change from baseline on DASS-21 score;Patient satisfaction score;Incidence of new onset diabetes nephropathy;Incidence of retinopathy in newly diagnosed diabetes;Incidence of new onset diabetes neuropathy;Incidence of new onset diabetes related lower extremity arterial disease;Incidence of newly diagnosed diabetes foot;Progression of albuminuria;Progression of diabetes retinopathy;Progression of lower extremity arterial disease in diabetes;Progression of diabetes foot;Incidence of hospitalization due to major infections/acute complications; Incidence of malignant tumors;Incidence rate of all-cause death;Long term cost-effectiveness of 'in-person Remote' Holonomic Diabetes Self-Management Support model;MACE incidence of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, revascularization, heart failure and nonfatal stroke);

Countries

China

Contacts

Public ContactLi Ang & Zhang Junqing

Peking University First Hospital

liang850513@hotmail.com+86 136 8133 8795

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026